RecruitingPhase 3NCT05156398
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 Years of Age
Sponsor
Pfizer
Enrollment
640 participants
Start Date
Feb 28, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine.
Eligibility
Min Age: 6 YearsMax Age: 17 Years
Inclusion Criteria9
- Subject has at least a 6 month history of migraine (with or without aura) and including the following:
- or less headache days per month during the 3 month period prior to the Screening Visit
- or more migraine days during the Observation Period
- or less headache days during the Observation Period
- Pediatric Migraine Disability Assessment Scale (PedMIDAS) Disability Score of \>10 to ≤50, indicating mild (score of 11 to 30) or moderate (score of 31 to 50) disruption in daily activities, as assessed at the Baseline (Randomization) Visit
- Ability to verbally distinguish migraine attacks from tension/cluster or other types of headaches
- Migraine attacks, on average, lasting 4 - 72 hours if untreated
- Subjects on prophylactic migraine medication are permitted to remain on therapy if the dose has been stable for at least 3 months (12 weeks) prior to the Screening Phase, and the dose is not expected to change during the course of the study. 2) Male and female subjects ≥ 6 to \<18 years; subjects must be less than 18 at the time of signing assent / consent.
- )Subjects must have a weight of ≥40 kg (child cohort requirement ≥15 kg) at the Screening Visit.
Exclusion Criteria9
- Subjects with a history of basilar migraine, cluster headaches, or hemiplegic migraine
- The subject has a continuous migraine (defined as an unrelenting headache) within 1 month prior to Screening Visit.
- The subject has a history or diagnosis of complications of migraine
- The subject has a confounding and clinically significant pain syndrome that may interfere with the subject's ability to participate in this study.
- The subject has any current psychiatric condition that is uncontrolled and/or untreated for a minimum of 6 months prior to the Screening Visit. Subjects with a lifetime history of psychosis and/or mania are excluded.
- History of suicidal behavior or the subject is at risk of self-harm or harm to others.
- History of major psychiatric disorder.
- The subject has a current diagnosis or history of substance abuse
- The subject has a history of moderate or severe head trauma or other neurological disorder (including seizure disorder) or systemic medical disease that is, in the investigator's opinion, likely to affect central nervous system functioning.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGRimegepant
Rimegepant 75mg or 50mg (2 X 25mg) ODT
DRUGPlacebo
Matching placebo 75mg or 50mg (2 X 25mg) ODT
Locations(90)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05156398
Related Trials
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
NCT0697205623 locations
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
NCT06241313149 locations
Mind Body Balance for Pediatric Migraine
NCT047156852 locations
MMA Embolization for Refractory Chronic Migraine
NCT067358337 locations
NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder
NCT056697031 location